Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study

Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial

(2022) Didier Jutras-Aswad et al.   AMERICAN JOURNAL OF PSYCHIATRY

Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: exploratory results from an open-label, pragmatic randomized controlled trial

(2022) Christina McAnulty et al.   DRUG AND ALCOHOL DEPENDENCE

Polysubstance use before and during treatment with medication for opioid use disorder: Prevalence and association with treatment outcomes

(2022) Amanda M. Bunting et al.   JOURNAL OF SUBSTANCE ABUSE TREATMENT

Predictors of crystal methamphetamine use initiation or re-initiation among people receiving opioid agonist therapy: A prospective cohort study

(2022) Zishan Cui et al.   DRUG AND ALCOHOL DEPENDENCE

Opioid agonist therapy engagement and crystal methamphetamine use: The impact of unregulated opioid use in Vancouver, Canada

(2022) Zishan Cui et al.   INTERNATIONAL JOURNAL OF DRUG POLICY

The relationship between crystal methamphetamine use and methadone retention in a prospective cohort of people who use drugs

(2021) Lindsay Mackay et al.   DRUG AND ALCOHOL DEPENDENCE

Pharmacotherapies for cannabis use disorder: A systematic review and network meta-analysis

(2021) Anees Bahji et al.   INTERNATIONAL JOURNAL OF DRUG POLICY

Changes in substance use in relation to opioid agonist therapy among people who use drugs in a Canadian setting

(2020) Huiru Dong et al.   DRUG AND ALCOHOL DEPENDENCE

Retention of patients in opioid substitution treatment: A systematic review

(2020) Aisling Máire O’Connor et al.   PLoS One

Methamphetamine Use and Its Correlates among Individuals with Opioid Use Disorder in a Midwestern U.S. City

(2020) Raminta Daniulaityte et al.   SUBSTANCE USE & MISUSE

Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis

(2020) Vitor S. Tardelli et al.   PSYCHOPHARMACOLOGY

Opioid-sparing effects of cannabinoids: Myth or reality?

(2020) Bernard Le Foll   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Medication Treatment of Opioid Use Disorder

(2019) James Bell et al.   BIOLOGICAL PSYCHIATRY

Frequency of cannabis and illicit opioid use among people who use drugs and report chronic pain: A longitudinal analysis

(2019) Stephanie Lake et al.   PLOS MEDICINE

Cannabis Use and Risk of Prescription Opioid Use Disorder in the United States

(2018) Mark Olfson et al.   AMERICAN JOURNAL OF PSYCHIATRY

The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale

(2018) M. Eugenia Socias et al.   Contemporary Clinical Trials

Canadian trends in opioid-related mortality and disability from opioid use disorder from 1990 to 2014 through the lens of the Global Burden of Disease Study

(2018) Heather M. Orpana et al.   Health Promotion and Chronic Disease Prevention in Canada-Research Policy and Practice

Pharmacotherapy for amphetamine dependence: A systematic review

(2018) Nicole K. Lee et al.   DRUG AND ALCOHOL DEPENDENCE

Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis

(2017) Suzanne Nielsen et al.   NEUROPSYCHOPHARMACOLOGY

Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans

(2016) Michelle R. Lofwall et al.   DRUG AND ALCOHOL DEPENDENCE

Benzodiazepine use during buprenorphine treatment for opioid dependence: Clinical and safety outcomes

(2013) Zev Schuman-Olivier et al.   DRUG AND ALCOHOL DEPENDENCE